The Contact Study is a clinical research study that will test whether dimebon (latrepirdine) safely improves cognition (thinking and awareness), behaviour, the ability to care for oneself, daily functioning, and quality of life in patients with moderate to severe Alzheimer's disease who are taking Aricept^® (also known as donepezil HCI tablets).

The Contact Study is taking place in Europe (Ireland, Italy, Portugal, Spain, and the UK) and South America (Argentina, Brazil, and Chile).

Dimebon (latrepirdine) has a unique mechanism of action, distinct from currently available treatments. In preclinical studies, dimebon has been shown to protect brain cells from damage and enhance brain cell survival, potentially by stabilising and improving mitochondrial function.

Aricept^® is a registered trademark of Eisai Co., Ltd.